SROBMS 2025 Symposium

SROBMS 2025 SYMPOSIUM– PROGRAM

24.10. FRIDAY

13.00-13.15 Opening – Assoc. Prof. Dr. Daniel Grigorie, SROBMS President

13.15-14.15 Denosumab – Long-term treatment effects and denosumab discontinuation. Goal-directed therapy with denosumab – Daniel Grigorie, Carol Davila University of Medicine, National Institute of Endocrinology, Bucharest, Romania (supported by AMGEN)

14.15-15.15 Goal-directed treatment of osteoporosis – the importance of initial and sequential treatment choices – Bente Langdahl, Aarhus University, Denmark

15.15-15.45 Coffee/Lunch Break

15.45-16.45 Genetics in Mineral Metabolism for Clinicians – Michael Mannstadt, Harvard Medical School, Massachusetts General Hospital, Boston, USA

16.45-17.30 Clinical cases session – Madalina Boboc, Teodor Oprea, Laura Ilinca; Comments: Daniel Grigorie

17.30-17.50 Coffee Break

17.50-18.30 Patients at imminent risk for fracture. Goal-directed therapy with teriparatide – Daniel Grigorie, Carol Davila University of Medicine, National Institute of Endocrinology, Bucharest, Romania (supported by STADA)

18.30-19.00 Romania’s experience with primary hyperparathyroidism: an East-West comparative view – Diana Coles, Carol Davila University of Medicine, National Institute of Endocrinology, Bucharest, Romania

19.00-19.30 SROBMS Meeting

25.10. SATURDAY

8.30-09.45 Clinical cases session – Alina Sucaliuc, Diana Coles, Diana Anghel, Paula Ardelean; Comments: Daniel Grigorie

9.45-10.15 Risedronate position from the goal-treatment perspective – Daniel Grigorie, Carol Davila University of Medicine, National Institute of Endocrinology, Bucharest, Romania (supported by THERAMEX)

10.15-10.45 Cofee break

10.45-11.30 Managing peri- and postmenopause- What’s new? – Paula Briggs, Liverpool Womens NHS Foundation Trust, UK

11.30-12.15 Osteoporosis in premenopausal women and young men – Carola Zillikens, Erasmus Medical Center Rotterdam, The Netherlands

12.15-13.00 Postmenopausal Hormone Therapy in the post-WHI times

Daniel Grigorie, Carol Davila University of Medicine, National Institute of Endocrinology, Bucharest, Romania (supported by THERAMEX)